As of 2026-09-20, the EV/EBITDA ratio of Kymera Therapeutics Inc (KYMR) is -28.29. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KYMR's latest enterprise value is 9,564.05 mil USD. KYMR's TTM EBITDA according to its financial statements is -338.09 mil USD. Dividing these 2 quantities gives us the above KYMR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.5x - 16.7x | 15.9x |
| Forward P/E multiples | 17.2x - 19.8x | 18.6x |
| Fair Price | (69.21) - (67.15) | (69.41) |
| Upside | -158.8% - -157.0% | -159.0% |
| Date | EV/EBITDA |
| 2026-09-17 | -28.47 |
| 2026-09-16 | -27.94 |
| 2026-09-15 | -27.17 |
| 2026-09-14 | -27.53 |
| 2026-09-11 | -27.61 |
| 2026-09-10 | -28.11 |
| 2026-09-09 | -27.72 |
| 2026-09-08 | -27.98 |
| 2026-09-04 | -28.20 |
| 2026-09-03 | -28.17 |
| 2026-09-02 | -28.50 |
| 2026-09-01 | -28.60 |
| 2026-08-31 | -28.55 |
| 2026-08-28 | -28.39 |
| 2026-08-27 | -28.89 |
| 2026-08-26 | -30.19 |
| 2026-08-25 | -30.45 |
| 2026-08-24 | -29.09 |
| 2026-08-21 | -28.79 |
| 2026-08-20 | -29.20 |
| 2026-08-19 | -30.61 |
| 2026-08-18 | -29.17 |
| 2026-08-17 | -29.18 |
| 2026-08-14 | -28.20 |
| 2026-08-13 | -27.48 |
| 2026-08-12 | -27.38 |
| 2026-08-11 | -26.31 |
| 2026-08-10 | -26.06 |
| 2026-08-07 | -25.80 |
| 2026-08-06 | -25.53 |
| 2026-08-05 | -25.30 |
| 2026-08-04 | -25.04 |
| 2026-08-03 | -24.05 |
| 2026-07-31 | -24.80 |
| 2026-07-30 | -25.68 |
| 2026-07-29 | -25.25 |
| 2026-07-28 | -25.47 |
| 2026-07-27 | -26.42 |
| 2026-07-24 | -26.54 |
| 2026-07-23 | -26.50 |
| 2026-07-22 | -26.49 |
| 2026-07-21 | -27.22 |
| 2026-07-20 | -26.66 |
| 2026-07-17 | -27.81 |
| 2026-07-16 | -27.37 |
| 2026-07-15 | -27.41 |
| 2026-07-14 | -26.91 |
| 2026-07-13 | -26.50 |
| 2026-07-10 | -28.68 |
| 2026-07-09 | -28.59 |